Transgene gains from Roche deal
French biopharmaceutical firm Transgene has posted a strong increase in total revenues and a move into profitability for the first six months of 2007, helped by progress for its strategic partnership with Swiss drug major Roche on TG 4001/R3484, in development for the treatment of precancerous cervical lesions caused by human papilloma virus infection.
Turnover for the reporting period reached 24.7 million euros ($33.7 million) compared with 2.8 million in the like, year-earlier six months, resulting in a net profit of 8.5 million euros versus a loss of 10.6 million euros. Contributing to this result were payments from Roche, including 13.0 million euros upfront and a 10.0 million-euro near-term milestone received in June.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze